We are live on ! Find out more
IDYA icon

IDEAYA Biosciences

110 hedge funds and large institutions have $820M invested in IDEAYA Biosciences in 2021 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

238% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 8

109% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 23

21% more funds holding

Funds holding: 91110 (+19)

4.61% more ownership

Funds ownership: 85.59%90.2% (+4.6%)

2% less capital invested

Capital invested by funds: $838M → $820M (-$17.6M)

17% less funds holding in top 10

Funds holding in top 10: 65 (-1)

Holders
110
Holders Change
+19
Holders Change %
+20.88%
% of All Funds
1.69%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.08%
New
27
Increased
48
Reduced
23
Closed
8
Calls
$950K
Puts
Net Calls
+$950K
Net Calls Change
-$439K
Name Holding Trade Value Shares
Change
Change in
Stake
HS
51
HighVista Strategies
Massachusetts
$960K +$944K +40,619 New
Barclays
52
Barclays
United Kingdom
$940K +$608K +26,173 +193%
Morgan Stanley
53
Morgan Stanley
New York
$926K +$274K +11,810 +43%
RhumbLine Advisers
54
RhumbLine Advisers
Massachusetts
$902K +$67.1K +2,887 +8%
Allspring Global Investments
55
Allspring Global Investments
North Carolina
$736K +$724K +31,170 New
Principal Financial Group
56
Principal Financial Group
Iowa
$629K +$618K +26,598 New
PAM
57
Panagora Asset Management
Massachusetts
$589K +$6.85K +295 +1%
Millennium Management
58
Millennium Management
New York
$549K +$296K +12,741 +122%
TCM
59
Tekla Capital Management
Massachusetts
$484K +$475K +20,454 New
New York State Common Retirement Fund
60
New York State Common Retirement Fund
New York
$479K -$720 -31 -0.2%
Deutsche Bank
61
Deutsche Bank
Germany
$471K +$24.7K +1,063 +6%
CS
62
Credit Suisse
Switzerland
$454K +$446K +19,179 New
AIG
63
American International Group
New York
$412K -$12.1K -521 -3%
Victory Capital Management
64
Victory Capital Management
Texas
$398K +$391K +16,828 New
JP Morgan Chase
65
JP Morgan Chase
New York
$383K -$200K -8,594 -35%
Jane Street
66
Jane Street
New York
$363K +$357K +15,361 New
SG Americas Securities
67
SG Americas Securities
New York
$360K -$195K -8,400 -36%
TRCT
68
Tower Research Capital (TRC)
New York
$348K +$261K +11,257 +324%
GCP
69
GSA Capital Partners
United Kingdom
$337K +$331K +14,263 New
VOYA Investment Management
70
VOYA Investment Management
Georgia
$303K -$2.46M -105,798 -89%
Invesco
71
Invesco
Georgia
$300K -$5.33M -229,485 -95%
RAM
72
Redmond Asset Management
Virginia
$299K +$16K +689 +6%
ProShare Advisors
73
ProShare Advisors
Maryland
$297K +$4.04K +174 +1%
AQR Capital Management
74
AQR Capital Management
Connecticut
$292K +$287K +12,336 New
Two Sigma Advisers
75
Two Sigma Advisers
New York
$274K -$955K -41,100 -78%

IDYA Hedge Fund Activity: Q4 2021 in Review

110 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in IDEAYA Biosciences (IDYA) for Q4 2021, worth a combined $820M — down 2.1% from $838M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new IDYA positions and 8 closed out — a net gain of 19 holders — while 48 added to existing stakes and 23 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $22.3M. The largest seller was RTW Investments, cutting an estimated $17.3M.

  • 110 institutional investors held IDEAYA Biosciences (IDYA) as of Q4 2021, up from 91 in Q3 2021.
  • Funds reported $820M of IDEAYA Biosciences stock for Q4 2021, down 2.1% quarter-over-quarter.
  • 27 funds opened new IDEAYA Biosciences positions in Q4 2021 and 8 closed out, a net change of +19 holders.
  • The largest IDEAYA Biosciences buyer in Q4 2021 was Fidelity Investments, an estimated $22.3M added.
  • The largest IDEAYA Biosciences seller in Q4 2021 was RTW Investments, an estimated $17.3M sold.

Based on aggregated 13F filings for Q4 2021.